EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase II)Multizentrische StudieOpen Access · CC BY 4.0

Deucravacitinib in patients with inflammatory bowel disease: 12-week efficacy and safety results from 3 randomized phase 2 studies in Crohn’s disease and ulcerative colitis

Geert D'Haens iD, Silvio Danese iD, Remo Panaccione iD, David T Rubin, Laurent Peyrin-Biroulet, Katsuyoshi Matsuoka, Edward V Loftus, Taku Kobayashi iD, Walid Elsharkawi, Rosa Miceli, Samia Ahmed, Yi Luo und 5 weitere

Journal of Crohn's and Colitis · 2025

DOI: 10.1093/ecco-jcc/jjaf080 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Crohn's and Colitis, 2025. Verfasst von Geert D'Haens und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Hepatology, Amsterdam University Medical Centers, Amsterdam, The Netherlands. Hauptthemen laut MEDLINE: Colitis, Ulcerative, Crohn Disease, Protein Kinase Inhibitors. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bristol Myers Squibb.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aims Tyrosine kinase 2 is a downstream intracellular mediator of interleukin-23 signaling, which has a key role in the pathogenesis of inflammatory bowel disease. Deucravacitinib is a novel, oral, selective, allosteric tyrosine kinase 2 inhibitor currently approved for the treatment of adults with moderate to severe plaque psoriasis.

Methods

Here we describe 3 randomized, double-blind, placebo-controlled phase 2 studies of deucravacitinib in patients with moderately to severely active Crohn’s disease (LATTICE-CD [NCT03599622]) or ulcerative colitis (LATTICE-UC [NCT03934216] and IM011-127 [NCT04613518]). Patients were randomized to receive placebo or twice-daily deucravacitinib 3 or 6 mg (LATTICE-CD), 6 mg (LATTICE-UC), or 12 mg (IM011-127) for 12 weeks. Coprimary endpoints for LATTICE-CD were clinical remission and endoscopic response at week 12. The primary endpoint was clinical remission (per modified Mayo score) at week 12 for LATTICE-UC and clinical response (per modified Mayo score) at week 12 for IM011-127.

Results

A total of 239 (LATTICE-CD), 131 (LATTICE-UC), and 38 (IM011-127) patients were randomized. The primary endpoints were not met for all 3 studies, which resulted in early study termination for LATTICE-CD and IM011-127. High efficacy rates were observed in placebo groups throughout the studies. In all studies, the safety profile of deucravacitinib was consistent with the known safety profile observed in patients with psoriasis, and no new safety signals were observed.

Conclusions

Deucravacitinib at multiple doses did not demonstrate significant clinical benefit vs placebo in moderately to severely active Crohn’s disease or ulcerative colitis. Deucravacitinib was safe and well tolerated.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colitis, UlcerativeCrohn DiseaseProtein Kinase InhibitorsHumansMaleFemaleAdultDouble-Blind MethodMiddle AgedTreatment OutcomeRemission Induction

Stichwörter der Autor:innen

Crohn’s diseaseDeucravacitinibefficiacysafetyulcerative colitis

Substanzen

Protein Kinase Inhibitors

Autor:innen und Institutionen

  • Department of Gastroenterology and Hepatology, Amsterdam University Medical Centers, Amsterdam, The Netherlands.
  • Department of Gastroenterology and Endoscopy, IRCCS Ospedale San Raffaele and Vita-Salute San Raffaele University, Milan, Italy.
  • Department of Medicine, Inflammatory Bowel Disease Clinic, Calgary, Alberta, Canada.
  • Inflammatory Bowel Disease Center, University of Chicago Medicine, Chicago, IL, United States.
  • Department of Gastroenterology, INFINY Institute, INSERM NGERE, CHRU Nancy, Vandœuvre-lès-Nancy, France.
  • Groupe Hospitalier Privé Ambroise Paré - Hartmann, Paris IBD Center, Neuilly sur Seine, France.

ORCID-Profile: Geert D'Haens, Silvio Danese, Remo Panaccione, Taku Kobayashi, Stefan Schreiber

Förderung

  • Bristol Myers Squibb

Zitieren

APA

D'Haens, G., Danese, S., Panaccione, R., Rubin, D. T., Peyrin-Biroulet, L., Matsuoka, K., Loftus, E. V., Kobayashi, T., Elsharkawi, W., Miceli, R., Ahmed, S., Luo, Y., Napoli, A., Vaile, J., Dornic, Q., Patel, A., & Schreiber, S. (2025). Deucravacitinib in patients with inflammatory bowel disease: 12-week efficacy and safety results from 3 randomized phase 2 studies in Crohn’s disease and ulcerative colitis. Journal of Crohn's and Colitis. https://doi.org/10.1093/ecco-jcc/jjaf080

Vancouver

D'Haens G, Danese S, Panaccione R, Rubin DT, Peyrin-Biroulet L, Matsuoka K, et al. Deucravacitinib in patients with inflammatory bowel disease: 12-week efficacy and safety results from 3 randomized phase 2 studies in Crohn’s disease and ulcerative colitis. Journal of Crohn's and Colitis. 2025. doi:10.1093/ecco-jcc/jjaf080

BibTeX
@article{DHaens2025,
  author = {D'Haens, Geert and Danese, Silvio and Panaccione, Remo and Rubin, David T and Peyrin-Biroulet, Laurent and Matsuoka, Katsuyoshi and Loftus, Edward V and Kobayashi, Taku and Elsharkawi, Walid and Miceli, Rosa and Ahmed, Samia and Luo, Yi and Napoli, Andrew and Vaile, John and Dornic, Quentin and Patel, Aditya and Schreiber, Stefan},
  title = {Deucravacitinib in patients with inflammatory bowel disease: 12-week efficacy and safety results from 3 randomized phase 2 studies in Crohn’s disease and ulcerative colitis},
  journal = {Journal of Crohn's and Colitis},
  year = {2025},
  doi = {10.1093/ecco-jcc/jjaf080}
}
Kostenlos starten →